Information Provided By: 
Fly News Breaks for December 11, 2018
JAZZ
Dec 11, 2018 | 16:06 EDT
Oppenheimer analyst Esther Rajavelu started Jazz Pharmaceuticals with an Outperform rating and $180 price target. The company has laid the groundwork to sustain its sleep franchise post Xyrem generics, Rajavelu tells investors in a research note. The analyst believes Jazz has a "solid" base business with its central nervous system-related sleep disorders franchise and a late-stage pipeline with "several" near-term catalysts.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
